(HealthDay)—Sulfonylureas as second-line drugs for type 2 diabetes are associated with an increased risk of cardiovascular and hypoglycemic events compared
Continue reading »![](https://mypharmacynews.com/wp-content/uploads/sites/11/2018/07/sulfonylurea.jpg)
mypharmacynews.com
Home »
(HealthDay)—Sulfonylureas as second-line drugs for type 2 diabetes are associated with an increased risk of cardiovascular and hypoglycemic events compared
Continue reading »Mayo Clinic researchers, reporting results of the SMART study, have shown that abnormal results on a stress electrocardiogram are an
Continue reading »